NVision Imaging Raises $30M Series A to Deploy Quantum-Powered Polarizers, Ushering in a New Era of Adaptive Cancer Treatment
Summary
Leveraging advances in quantum physics, NVision is powering the next generation of metabolic MRIs for faster and more accurate cancer diagnoses and treatment assessmentULM, Germany, June 22, 2023--(BUSINESS WIRE)--NVision Imaging, a developer of MRI polarizers and hyperpolarized imaging agents, announced today that they have closed a $30M Series A round, with an additional $19.5M in funding from the German government. The company will use the funds to advance the development and deployment of the NVision Polarizer and usher in a new era of metabolic MRI capabilities and ultimately, adaptive cancer treatment. The round was led by Playground Global, with participation by return investors b-to-v and new participation from Pathena Investments, Entree Capital, Lauder Family, ES Kapital, and Sparkassenkapital Ulm, bringing their total funding to $35M, not including the government funds.Traditional MRIs detect slow-changing effects of a cancer therapy at the tissue level, which can take months to show up from the onset of treatment. Based on a novel parahydrogen-induced polarization (PHIP) technique, the NVision team is applying breakthroughs in quantum physics, chemistry, and engineering to revolutionize metabolic MRIs.The ability to diagnose earlier, assess treatment response faster, and non-invasively understand tumor aggressiveness is the foundation for a new era of adaptive cancer treatment. "With a partnership already in place with Siemens Healthineers, a leading provider of MRI technology, plans to deploy systems at over 50 of the worlds top cancer centers by 2025, and a signed collaboration with Memorial Sloan Kettering, NVision is poised for market disruption.NVisions quantum metabolic polarizers are currently planned for preclinical use in 2023, and will use the funding to deploy their technology for human care in the coming years.NVision was founded by a team of leading quantum physicists, engineers, and chemists, and is located in Ulm, Baden-W\xfcrttemberg.To learn more their breakthrough technology, visit NVision at nvision-imaging.comNVision is a developer of MRI polarizers and hyperpolarized imaging agents.The companys hyperpolarization technology permits the assessment of human and animal metabolism by standard MRI, enabling advanced preclinical and clinical applications, including novel cancer diagnosis and monitoring of response to therapy.